

REMARKS

The claims have been amended to reduce the filing fees and/or place the claims in a more traditional U.S. format. Claims 1-34 have been canceled, without prejudice. Claims 35-62 have been added and are pending. No new matter has been added.

The requisite inventors' Declaration was filed during the International Phase and a copy of the same is attached.

The specification has been amended to include the attached Sequence Listing. The attached paper and computer readable copies of the sequence listing are the same. No new matter has been added. A separate Statement to this effect is attached.


Return of an initialed copy of the attached PTO 1449 Form, pursuant to MPEP § 609, is requested.

A Notification/Notice of Acceptance is requested with a Filing Receipt and an early and favorable action on the merits of the claimed invention.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By:



B. J. Sadoff

Reg. No. 36,663

BJS:Imy

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

ABSTRACT OF THE DISCLOSURE

The present invention relates to a mutated gene coding for a mutant LAT protein leading to an exaggerated TH2 differentiation. The invention relates to biological structures containing said mutant, particularly, non-human LAT gene mutated animals, plasmids, chromosomal DNA's, embryos comprising said mutated gene, and applications thereof. The invention further relates to screening method for drug useful for treatment against asthma and allergy. Otherwise, the invention relates to method for producing IgE antibodies.